TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00596362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVASTIN
Description: a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
Study: NCT03094039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilatory support while attached to the cord
Description: Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
Study: NCT01574079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy plus Mirror Therapy
Description: The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
Study: NCT01623687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty components are for the femur (Corail stem)
Description: Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
Study: NCT01421849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture implantation
Description: In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months.
Study: NCT02865343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study: NCT02491060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121 Lotion
Description: Investigational Product: IDP-121 Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: Comparator Product: IDP-121 Vehicle Lotion
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - Stroop task
Description: 2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - Stroop task
Description: 2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - MID task
Description: 2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI - MID task
Description: 2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Signal Task
Description: Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
Study: NCT03506672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practices
Description: Usual practices of formal caregivers regarding vocal behaviours
Study: NCT02797873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Signal Task
Description: Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCID-II
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCID-II
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDQ
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDQ
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASRS
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASRS
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AQ
Description: See Detailed Study Description.
Study: NCT02865343

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study: NCT03283982

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Ventral Hernia Repair with IPOM
Description: Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Ventral Hernia Repair with IPOM
Description: Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
Study: NCT04319679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: 6 times during 2 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: 6 times during 2 weeks
Study: NCT02043379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
Study: NCT00211562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Omega 3, Vitamin E+C
Description: No adverse event nor SAE noted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Omega 3, Vitamin E+C
Description: No adverse event nor SAE noted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Omega 3, Vitamin E+C
Description: No adverse event nor SAE noted.
Study: NCT02089282

Intervention type: DEVICE
Intervention: Ultrasound
Study: NCT02955628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib-RICE
Description: Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
Study: NCT03093025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-121 10 mg
Description: Orally taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-121 50 mg
Description: Orally taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally taken once daily
Study: NCT02863822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choose My Plate Diet
Description: Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
Study: NCT02043379

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
Study: NCT04153071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPUS system
Description: Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
Study: NCT00657826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm
Description: Isolated aortic valve replacement with a size 19mm valve
Study: NCT02283151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet nutrition bar
Description: The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.

Intervention type: OTHER
Group type: OTHER
Intervention: energy-restricted diet
Description: The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
Study: NCT01322308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg tablet QD (taken once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet taken once a day
Study: NCT02370446

Intervention type: OTHER
Intervention: personalized medication log

Intervention type: OTHER
Intervention: standard of care

Intervention type: BEHAVIORAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Intervention: Cognitive Interview
Study: NCT02749123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 5% patch
Description: 10cmx 14 cm transdermal patch sealed in its own pouch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine 3.6%, menthol 1.25%
Description: 10cmx 14 cm transdermal patch sealed in its own pouch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 3.6%, menthol 1.25%
Description: 10cmx 14 cm transdermal patch sealed in its own pouch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
Study: NCT01240265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 150,000 IU orally given once

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5000 IU given orally daily for 28 days
Study: NCT03233269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
Study: NCT02197455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Administration
Description: 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
Study: NCT03733431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gammacore device
Description: Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gammacore device
Description: Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gammacore sham device
Description: Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
Study: NCT04254042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Arginine
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer
Description: 30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study: NCT03355443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroflexion
Description: Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-examination
Description: Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
Study: NCT00911443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg
Description: Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Thymosin-alpha-1 3.2 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine + Interferon alpha
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study: NCT00002779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Study: NCT02592187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReMemory-MCI training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Study: NCT02531243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALMS
Description: Family Therapy; Multi-user Biofeedback Videogames
Study: NCT03729362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase Alfa
Description: Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alglucosidase Alfa
Description: Participants received an IV infusion dose over a 4-hour duration Q2W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
Study: NCT00967928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Whole Pelvis Radiation Therapy
Description: Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
Study: NCT04491097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panavia V5 resin cement
Description: Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panavia F2.0 resin cement
Description: Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
Study: NCT06738693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Fixation
Description: External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate
Description: ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
Study: NCT03315806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: 140 mL of beetroot juice cointaning approximately 9 mmol of nitrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140 mL of beetroot juice isent of nitrate
Study: NCT01046097

Intervention type: BIOLOGICAL
Intervention: Synflorix™
Description: Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
Study: NCT02415127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon γ-1b
Description: The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
Study: NCT03669250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN058
Description: CVN058 will be given at two doses, a low does and a high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN058
Description: CVN058 will be given at two doses, a low does and a high dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: inactive placebo
Study: NCT00624286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.